Evidence map›Paper›PMID 29299659›Full record

ArticleCancer immunology, immunotherapy : CII2018

Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells.

Tina Nham, Sophie M Poznanski, Isabella Y Fan, Mira M Shenouda, Marianne V Chew, Amanda J Lee, Fatemeh Vahedi, Yalda Karimi, Martin Butcher, Dean A Lee and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 47 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Origin of Hypofunctional CD103European journal of immunology · 2025
    Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Immune Tumor Microenvironment in Ovarian Cancer Ascites.International journal of molecular sciences · 2022
    Review
  18. The adipocyte microenvironment and cancer.Cancer metastasis reviews · 2022
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Tina NhamDepartment of Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University, Rm 4015 Michael DeGroote Centre for Learning and Discovery, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Sophie M PoznanskiDepartment of Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University, Rm 4015 Michael DeGroote Centre for Learning and Discovery, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Isabella Y FanDepartment of Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University, Rm 4015 Michael DeGroote Centre for Learning and Discovery, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Mira M ShenoudaDepartment of Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University, Rm 4015 Michael DeGroote Centre for Learning and Discovery, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Marianne V ChewDepartment of Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University, Rm 4015 Michael DeGroote Centre for Learning and Discovery, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Amanda J LeeDepartment of Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University, Rm 4015 Michael DeGroote Centre for Learning and Discovery, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Fatemeh VahediDepartment of Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University, Rm 4015 Michael DeGroote Centre for Learning and Discovery, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Yalda KarimiDepartment of Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University, Rm 4015 Michael DeGroote Centre for Learning and Discovery, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Martin ButcherJuravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
Dean A LeeThe Research Institute at Nationwide Children's Hospital, Ohio State University, Columbus, OH, USA.
Hal HirteDivision of Medical Oncology, Department of Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada.
Ali A AshkarDepartment of Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University, Rm 4015 Michael DeGroote Centre for Learning and Discovery, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada. ashkara@mcmaster.ca.ORCID http://orcid.org/0000-0003-1139-1468
McMaster University Medical Centre · CAJuravinski Cancer Centre · CANationwide Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OC) is the leading cause of gynecological cancer-related death in North America. Most ovarian cancer patients (OCPs) experience disease recurrence after first-line surgery and chemotherapy; thus, there is a need for novel second-line treatments to improve the prognosis of OC. Although peripheral blood-derived NK cells are known for their ability to spontaneously lyse tumour cells without prior sensitization, ascites-derived NK cells (ascites-NK cells) isolated from OCPs exhibit inhibitory phenotypes, impaired cytotoxicity and may play a pro-tumourigenic role in cancer progression. Therefore, it is of interest to improve the cytotoxic effector function of impaired OCP ascites-NK cells at the tumour environment. We investigated the efficacy of using an artificial APC-based ex vivo expansion technique to generate cytotoxic, expanded NK cells from previously impaired OCP ascites-NK cells, for use in an autologous model of NK cell immunotherapy. We are the first to obtain a log-scale expansion of OCP ascites-NK cells that upregulate the surface expression of activating receptors NKG2D, NKp30, NKp44, produce robust amounts of anti-tumour cytokines in the presence of OC cells and mediate direct tumour cytotoxicity against ascites-derived, primary OC cells obtained from autologous patients. Our findings demonstrate that it is possible to generate cytotoxic OCP ascites-NK cells from previously impaired OCP ascites-NK cells, which presents a promising immunotherapeutic target for the second-line treatment of OC. Future work should focus on evaluating the in vivo efficacy of autologous NK cell immunotherapy through the intraperitoneal delivery of NK cell expansion factors to a preclinical xenograft mouse model of human OC.

Indexed as

ImmunotherapyAscitesCell ProliferationCytokinesCytotoxicity, ImmunologicFemaleHumansKiller Cells, NaturalOvarian NeoplasmsTumor Cells, CulturedCytokinesAscitesAutologous natural killer cellsEx vivo NK cell expansionNatural killer cell cancer immunotherapyOvarian cancer

Identifiers

PMID29299659
PMCPMC11028100
OpenAlexW2782401996

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.